Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles.

Frutoso M, Morisseau S, Tamzalit F, Quéméner A, Meghnem D, Leray I, Jacques Y, Mortier E.

J Immunol. 2018 Jul 15;201(2):493-506. doi: 10.4049/jimmunol.1800086. Epub 2018 May 30.

PMID:
29848756
2.

Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization.

Quéméner A, Maillasson M, Arzel L, Sicard B, Vomiandry R, Mortier E, Dubreuil D, Jacques Y, Lebreton J, Mathé-Allainmat M.

J Med Chem. 2017 Jul 27;60(14):6249-6272. doi: 10.1021/acs.jmedchem.7b00485. Epub 2017 Jul 18.

PMID:
28657314
3.

Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.

Meghnem D, Morisseau S, Frutoso M, Trillet K, Maillasson M, Barbieux I, Khaddage S, Leray I, Hildinger M, Quéméner A, Jacques Y, Mortier E.

J Immunol. 2017 Jun 15;198(12):4563-4568. doi: 10.4049/jimmunol.1700046. Epub 2017 May 15.

4.

[Interleukin 2 revival: a revisited model and new therapeutic applications].

Jacques Y, Mortier E.

Med Sci (Paris). 2016 Jun-Jul;32(6-7):612-8. doi: 10.1051/medsci/20163206025. Epub 2016 Jul 12. Review. French.

5.

IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.

Desbois M, Le Vu P, Coutzac C, Marcheteau E, Béal C, Terme M, Gey A, Morisseau S, Teppaz G, Boselli L, Jacques Y, Béchard D, Tartour E, Cassard L, Chaput N.

J Immunol. 2016 Jul 1;197(1):168-78. doi: 10.4049/jimmunol.1600019. Epub 2016 May 23.

6.

Enriching a cellulose hydrogel with a biologically active marine exopolysaccharide for cell-based cartilage engineering.

Rederstorff E, Rethore G, Weiss P, Sourice S, Beck-Cormier S, Mathieu E, Maillasson M, Jacques Y, Colliec-Jouault S, Fellah BH, Guicheux J, Vinatier C.

J Tissue Eng Regen Med. 2017 Apr;11(4):1152-1164. doi: 10.1002/term.2018. Epub 2015 Mar 30.

PMID:
25824373
7.

Syndecan-1 regulates the biological activities of interleukin-34.

Segaliny AI, Brion R, Mortier E, Maillasson M, Cherel M, Jacques Y, Le Goff B, Heymann D.

Biochim Biophys Acta. 2015 May;1853(5):1010-21. doi: 10.1016/j.bbamcr.2015.01.023. Epub 2015 Feb 4.

8.

[Cut the cord, you're ready to set off on your own!].

Mortier E, Tamzalit F, Jacques Y, Morisseau S.

Med Sci (Paris). 2014 Oct;30(10):836-8. doi: 10.1051/medsci/20143010006. Epub 2014 Oct 14. French. No abstract available.

9.

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.

Vincent M, Teppaz G, Lajoie L, Solé V, Bessard A, Maillasson M, Loisel S, Béchard D, Clémenceau B, Thibault G, Garrigue-Antar L, Jacques Y, Quéméner A.

MAbs. 2014 Jul-Aug;6(4):1026-37.

10.

IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.

Tamzalit F, Barbieux I, Plet A, Heim J, Nedellec S, Morisseau S, Jacques Y, Mortier E.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8565-70. doi: 10.1073/pnas.1405514111. Epub 2014 May 27.

11.

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI.

Vincent M, Quéméner A, Jacques Y.

Oncoimmunology. 2013 Nov 1;2(11):e26441. Epub 2013 Oct 9.

12.

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.

Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, Caignard A, Messaoudene M, Aupérin A, Vielh P, Dessen P, Porta C, Mateus C, Ayyoub M, Valmori D, Eggermont A, Robert C, Zitvogel L.

Cancer Res. 2014 Jan 1;74(1):68-80. doi: 10.1158/0008-5472.CAN-13-1186. Epub 2013 Nov 6.

13.

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.

Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y.

Int J Cancer. 2013 Aug 1;133(3):757-65. doi: 10.1002/ijc.28059. Epub 2013 Feb 25.

14.

Multiplexed infectious protein microarray immunoassay suitable for the study of the specificity of monoclonal immunoglobulins.

Feron D, Charlier C, Gourain V, Garderet L, Coste-Burel M, Le Pape P, Weigel P, Jacques Y, Hermouet S, Bigot-Corbel E.

Anal Biochem. 2013 Feb 15;433(2):202-9. doi: 10.1016/j.ab.2012.10.012. Epub 2012 Oct 26.

PMID:
23103342
15.

Autonomous and extrinsic regulation of thymopoiesis in human immune system (HIS) mice.

Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Plet A, Weijer K, Jacques Y, Spits H, Di Santo JP.

Eur J Immunol. 2011 Oct;41(10):2883-93. doi: 10.1002/eji.201141586. Epub 2011 Aug 30.

16.

Despite an impaired response to IL-7, CD4+EM T cells from HIV-positive patients proliferate normally in response to IL-15 and its superagonist, RLI.

Pacheco Y, Solé V, Billaud E, Allavena C, Plet A, Ferré V, Garrigue-Antar L, Raffi F, Jacques Y, McIlroy D.

AIDS. 2011 Sep 10;25(14):1701-10. doi: 10.1097/QAD.0b013e328349a437.

PMID:
21673554
17.

Antibody-Hapten Recognition at the Surface of Functionalized Liposomes Studied by SPR: Steric Hindrance of Pegylated Phospholipids in Stealth Liposomes Prepared for Targeted Radionuclide Delivery.

Botosoa EP, Maillasson M, Mougin-Degraef M, Remaud-Le Saëc P, Gestin JF, Jacques Y, Barbet J, Faivre-Chauvet A.

J Drug Deliv. 2011;2011:368535. doi: 10.1155/2011/368535. Epub 2011 Jan 17.

18.

IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo.

Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Mention JJ, Plet A, Weijer K, Jacques Y, Becker PD, Guzman C, Soussan P, Kremsdorf D, Spits H, Di Santo JP.

Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6217-22. doi: 10.1073/pnas.1019167108. Epub 2011 Mar 28.

19.

Evolution of interleukin-15 for higher E. coli expression and solubility.

Béhar G, Solé V, Defontaine A, Maillasson M, Quéméner A, Jacques Y, Tellier C.

Protein Eng Des Sel. 2011 Mar;24(3):283-90. doi: 10.1093/protein/gzq107. Epub 2010 Nov 25.

PMID:
21109548
20.

Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation.

Perdreau H, Mortier E, Bouchaud G, Solé V, Boublik Y, Plet A, Jacques Y.

Eur Cytokine Netw. 2010 Dec;21(4):297-307. doi: 10.1684/ecn.2010.0207. Epub 2010 Nov 16.

21.

Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.

Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S.

Oncogene. 2011 Feb 24;30(8):990-1001. doi: 10.1038/onc.2010.479. Epub 2010 Nov 1.

PMID:
21042281
22.

Definition and characterization of an inhibitor for interleukin-31.

Venereau E, Diveu C, Grimaud L, Ravon E, Froger J, Preisser L, Danger Y, Maillasson M, Garrigue-Antar L, Jacques Y, Chevalier S, Gascan H.

J Biol Chem. 2010 May 14;285(20):14955-63. doi: 10.1074/jbc.M109.049163. Epub 2010 Mar 24.

23.

Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.

Bouchaud G, Mortier E, Flamant M, Barbieux I, Plet A, Galmiche JP, Jacques Y, Bourreille A.

Gastroenterology. 2010 Jun;138(7):2378-87. doi: 10.1053/j.gastro.2010.02.044. Epub 2010 Feb 23.

PMID:
20188102
24.

Oral insulin and buccal insulin: a critical reappraisal.

Heinemann L, Jacques Y.

J Diabetes Sci Technol. 2009 May 1;3(3):568-84. Review.

25.

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.

Bessard A, Solé V, Bouchaud G, Quéméner A, Jacques Y.

Mol Cancer Ther. 2009 Sep;8(9):2736-45. doi: 10.1158/1535-7163.MCT-09-0275. Epub 2009 Sep 1.

26.

IL-15 trans-presentation promotes human NK cell development and differentiation in vivo.

Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H, Di Santo JP.

J Exp Med. 2009 Jan 16;206(1):25-34. doi: 10.1084/jem.20082013. Epub 2008 Dec 22.

27.

Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells.

Lacreusette A, Barbieux I, Nguyen JM, Pandolfino MC, Dréno B, Jacques Y, Godard A, Blanchard F.

J Pathol. 2009 Apr;217(5):665-76. doi: 10.1002/path.2490.

PMID:
19097071
28.

Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.

Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, Khammari A, Dréno B, Jacques Y, Blanchard F, Godard A.

J Pathol. 2008 Dec;216(4):451-9. doi: 10.1002/path.2416.

PMID:
18798220
29.

The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha.

Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, Perdreau H, Jacques Y, Plet A.

J Mol Biol. 2008 Sep 26;382(1):1-12. doi: 10.1016/j.jmb.2008.07.019. Epub 2008 Jul 16.

PMID:
18656487
30.

The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer.

Badoual C, Bouchaud G, Agueznay Nel H, Mortier E, Hans S, Gey A, Fernani F, Peyrard S, -Puig PL, Bruneval P, Sastre X, Plet A, Garrigue-Antar L, Quintin-Colonna F, Fridman WH, Brasnu D, Jacques Y, Tartour E.

Cancer Res. 2008 May 15;68(10):3907-14. doi: 10.1158/0008-5472.CAN-07-6842.

31.

Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor.

Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, Jacques Y, Baratin M, Tomasello E, Vivier E.

Nat Immunol. 2007 Dec;8(12):1337-44. Epub 2007 Oct 28.

PMID:
17965716
32.

Ex vivo evaluation of bioadhesive films for buccal delivery of fentanyl.

Diaz del Consuelo I, Falson F, Guy RH, Jacques Y.

J Control Release. 2007 Sep 26;122(2):135-40. Epub 2007 May 23.

PMID:
17688966
33.

Docking of human interleukin-15 to its specific receptor alpha chain: correlation between molecular modeling and mutagenesis experimental data.

Quéméner A, Bernard J, Mortier E, Plet A, Jacques Y, Tran V.

Proteins. 2006 Nov 15;65(3):623-36.

PMID:
17001647
34.

Loss of oncostatin M receptor beta in metastatic melanoma cells.

Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, Godard A, Blanchard F.

Oncogene. 2007 Feb 8;26(6):881-92. Epub 2006 Aug 7.

PMID:
16909117
35.

The structure of the interleukin-15 alpha receptor and its implications for ligand binding.

Lorenzen I, Dingley AJ, Jacques Y, Grötzinger J.

J Biol Chem. 2006 Mar 10;281(10):6642-7. Epub 2005 Dec 23.

36.

Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, Plet A, Jacques Y.

J Biol Chem. 2006 Jan 20;281(3):1612-9. Epub 2005 Nov 11.

37.

Evaluation of pig esophageal mucosa as a permeability barrier model for buccal tissue.

Diaz Del Consuelo I, Pizzolato GP, Falson F, Guy RH, Jacques Y.

J Pharm Sci. 2005 Dec;94(12):2777-88.

PMID:
16258996
38.

Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.

Rabu C, Quéméner A, Jacques Y, Echasserieau K, Vusio P, Lang F.

J Biol Chem. 2005 Dec 16;280(50):41472-81. Epub 2005 Oct 4.

39.

Transport of fentanyl through pig buccal and esophageal epithelia in vitro: influence of concentration and vehicle pH.

Diaz Del Consuelo I, Falson F, Guy RH, Jacques Y.

Pharm Res. 2005 Sep;22(9):1525-9. Epub 2005 Aug 24.

PMID:
16132365
40.

Comparison of the lipid composition of porcine buccal and esophageal permeability barriers.

Diaz-Del Consuelo I, Jacques Y, Pizzolato GP, Guy RH, Falson F.

Arch Oral Biol. 2005 Dec;50(12):981-7. Epub 2005 Jun 13.

PMID:
15955526
41.

Expression of a bioactive recombinant human interleukin-11 in chicken HD11 cell line.

Léon A, Wang XM, Champion-Arnaud P, Sobczyk A, Pain B, Content J, Jacques Y, Valarché I.

Cytokine. 2005 Jun 21;30(6):382-90.

PMID:
15869884
42.
43.

Identification of an interleukin-15alpha receptor-binding site on human interleukin-15.

Bernard J, Harb C, Mortier E, Quéméner A, Meloen RH, Vermot-Desroches C, Wijdeness J, van Dijken P, Grötzinger J, Slootstra JW, Plet A, Jacques Y.

J Biol Chem. 2004 Jun 4;279(23):24313-22. Epub 2004 Mar 23.

44.

Soluble mannose 6-phosphate/insulin-like growth factor II (IGF-II) receptor inhibits interleukin-6-type cytokine-dependent proliferation by neutralization of IGF-II.

Duplomb L, Chaigne-Delalande B, Vusio P, Raher S, Jacques Y, Godard A, Blanchard F.

Endocrinology. 2003 Dec;144(12):5381-9. Epub 2003 Aug 28.

PMID:
12959977
45.

Characterization of a potent human interleukin-11 agonist.

Harmegnies D, Wang XM, Vandenbussche P, Leon A, Vusio P, Grötzinger J, Jacques Y, Goormaghtigh E, Devreese B, Content J.

Biochem J. 2003 Oct 1;375(Pt 1):23-32.

46.

Mutations in the immunoglobulin-like domain of gp190, the leukemia inhibitory factor (LIF) receptor, increase or decrease its affinity for LIF.

Bitard J, Daburon S, Duplomb L, Blanchard F, Vuisio P, Jacques Y, Godard A, Heath JK, Moreau JF, Taupin JL.

J Biol Chem. 2003 May 2;278(18):16253-61. Epub 2003 Feb 24.

47.

Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera.

Hermouet S, Godard A, Pineau D, Corre I, Raher S, Lippert E, Jacques Y.

Cytokine. 2002 Nov 24;20(4):178-83.

PMID:
12543083
48.

Engineering and use of (32)P-labeled human recombinant interleukin-11 for receptor binding studies.

Wang XM, Wilkin JM, Boisteau O, Harmegnies D, Blanc C, Vandenbussche P, Montero-Julian FA, Jacques Y, Content J.

Eur J Biochem. 2002 Jan;269(1):61-8.

49.

Identification of agonistic and antagonistic antibodies against gp190, the leukemia inhibitory factor receptor, reveals distinct roles for its two cytokine-binding domains.

Taupin JL, Legembre P, Bitard J, Daburon S, Pitard V, Blanchard F, Duplomb L, Godard A, Jacques Y, Moreau JF.

J Biol Chem. 2001 Dec 21;276(51):47975-81. Epub 2001 Oct 17.

50.

Characterization of an IL-2 mimetic with therapeutic potential.

Eckenberg R, Rose T, Moreau JL, Weil R, Gesbert F, Dubois S, Tello D, Bossus M, Gras H, Tartar A, Bertoglio J, Chouaïb S, Jacques Y, Alzari PM, Thèze J.

Cell Mol Biol (Noisy-le-grand). 2001 Jun;47(4):703-7. Review.

PMID:
11502078

Supplemental Content

Loading ...
Support Center